GSK reports promising early results in ovarian and womb cancer drug trial
GSK has revealed positive results for a treatment for gynaecological cancers as its chief executive, Luke Miels, seeks to speed up drug development at the group,The company said that in an early-stage trial Mocertatug Rezetecan, known as Mo-Rez, shrank or eliminated tumours in 62% of patients with ovarian cancer where chemotherapy had failed, and in 67% of those with endometrial cancer,Based in London, GSK has recently gained plaudits for its work on tackling superbugs, becoming one of just three big pharma companies globally that continue to invest in anti-microbial research,However, commercially GSK has been eclipsed in recent years by its bigger British rival AstraZeneca, which last year outstripped GSK’s near-£33bn turnover by more than £10bn and whose market value is more than twice as high,GSK acquired the Mo-Rez cancer treatment, an antibody-drug conjugate (ADC), from China’s Hansoh Pharma in late 2023, and has trialled it in 224 patients around the world, including the UK, over the past year.
Only a few patients needed to stop treatment because of side-effects, the most common being nausea.It is administered every three weeks via intravenous infusion.Combined with data from a separate, intermediate trial in China, these results give the British drugmaker the confidence to go straight to late-stage trials, with five clinical studies planned globally in the next few months, including on patients in the UK.Presenting the results at the Society of Gynecologic Oncology’s annual meeting on women’s cancer in Puerto Rico, Hesham Abdullah, GSK’s global head of cancer research and development, said: “Treatment of gynaecological cancers remains a major challenge, with a pressing need for new therapies that offer improved response rates.With Mo-Rez we now have compelling evidence of a promising clinical profile.
”Endometrial cancer affects 1.6 million women globally, with 417,000 new cases each year.Ovarian cancer affects 843,000 people, with 240,000 new cases annually.Speaking to journalists before the conference, Abdullah described Mo-Rez as a “key asset” in the company’s growing cancer portfolio.It is expected to be a blockbuster drug, with peak annual sales of more than £2bn, which GSK hopes will help it to achieve its 2031 sales target of £40bn.
Miels, an Australian who was brought in by his predecessor, Emma Walmsley, from AstraZeneca in 2017 and worked for Roche and Sanofi-Aventis, has announced several deals since taking the helm at GSK on 1 January, and vowed to show “scientific courage”.Abdullah said Miels, with whom he previously worked at AstraZeneca, had stepped up the pace of drug development.“The entire organisation is certainly really enjoying following this pace, the agility, and having the scientific courage.“His leadership style, the engagement, the strategic insight, the drug development expertise … you’re also seeing some of that come to life through the development programmes.”It has been less than a decade since GSK moved back into oncology under Walmsley, after GSK sold its cancer portfolio to Novartis in 2015 in a swap for the Swiss company’s vaccines business.
A few years ago GSK did not have any cancer drugs on the market but it now has four approved medicines and 13 in clinical development,Last year, oncology generated nearly £2bn in sales, up 43% from 2024, with sales of its endometrial cancer drug Jemperli soaring 89%,
Wigan edge out Wakefield in thriller to set up mouthwatering Saints semi-final
The winds of change that swept through Super League last year as Hull KR became the dominant force in the game have at stages already in 2026 threatened to become more akin to a hurricane – and no afternoon felt more seismic in defining that mood than this.Super League has been in desperate need of a new challenger for some time, which made Hull KR’s domestic treble last year all the more interesting. But this year, a new force has threatened to rise alongside the Robins, St Helens, Leeds and Wigan: that of Wakefield Trinity.One of rugby league’s grand old clubs historically, Wakefield have been nothing more than also-rans for much of the past 50 years, having not won a major trophy since the 1960s. But after widespread investment, a renovated Belle Vue and a squad that is joint top after the opening quarter of the season, they have all the hallmarks of a team ready to compete at the top again
Fury only wants Joshua but after 10 years of wrangling will superfight ever happen?
Just before midnight on Saturday, an hour after the first victory of his latest comeback, Tyson Fury paused in the midst of a familiar monologue about a predictable subject. He had just outclassed Arslanbek Makhmudov, the tough but limited Russian heavyweight, over 12 one‑sided rounds. But Fury wanted to talk only about Anthony Joshua and whether or not he and his old British rival would ever fight each other.In the lavish depths of Tottenham Hotspur Stadium, Fury sounded perplexed: “Ten years in the making and still, after all this time, there’s uncertainty if this fight’s gonna happen next. I’ve no idea
Gout Gout leaves onlookers dumbfounded with record-breaking run drawn from the future | Jack Snape
The sprint sensation was pushed to new heights in the 200m final by an unlikely opponent at the Australian Athletics ChampionshipsIt didn’t look good for Gout Gout. He had started the 200m final at the Australian Athletics Championships relatively well, and was positioned just off the lead at the start of the straight.But, there – who was that? The man wearing all black, two lanes on the inside. An athlete who appeared to match the global phenomenon step by step just when Gout was expected to pull away.It wasn’t Lachlan Kennedy, the 100m champion who has beaten Gout twice over 200m but who pulled out of this event early on Sunday
Gout Gout smashes 20-second barrier to set new 200m national record
Teenage sprint phenomenon Gout Gout has smashed his own national 200m record and become the first Australian to break the 20-second barrier in legal conditions as he sprinted to victory in 19.67sec at the athletics championships in Sydney.Aidan Murphy pushed the 18-year-old deep into the straight and finished with the second best 200m time by an Australian of 19.88sec, with a tailwind of +1.7m/s
Rory McIlroy aims for ‘freer’ state of mind in final round of Masters after losing six-shot lead
Rory McIlroy hopes to benefit from a “freer” state of mind on the final day of the Masters, despite the defending champion conceding he will have to improve markedly from round three to retain the Green Jacket. McIlroy saw his six-stroke lead evaporate on Saturday, meaning he enters the fourth round in a tie with Cameron Young at the top of the leaderboard. McIlroy was visibly short of his best during a one-over-par 73.The Northern Irishman can, however, pull upon the glory of 2025 at the same venue. “I’d like to think that I’ll play a little bit freer and I’ll play, like I’ve already got a Green Jacket, which I do,” McIlroy said
Cameron Young reels in Rory McIlroy with pack on their tails for Masters finale
Rory McIlroy began this Masters in the company of Cameron Young and will finish it in the company of Cameron Young. McIlroy arrived at this tournament as the holder of the Green Jacket. By Sunday night he will …? Goodness only knows. Day three proved predictions are a fool’s errand at the Masters.Such drama played out at Augusta National on Saturday that by close of play it was extraordinary to see McIlroy’s name still atop the leaderboard, albeit now with Young for company
Cream sherry: a forgotten taste that’s worth rediscovering
From soups and greens to roots, how to survive the ‘hungry gap’
Rachel Roddy’s recipe for hazelnut and chocolate cake | A kitchen in Rome
How to make cauliflower cheese using the whole plant – recipe | Waste not
A marmalade-dropper for Paddington Bear? | Letters
‘Before I can stop her, my daughter is licking crumbs from the table’: my search for the perfect kids’ menu